Price Hikes Protect Cephalon, Lining Up Nuvigil Ducks
This article was originally published in The Pink Sheet Daily
Firm to add sales reps after ending Takeda co-promotion deal.
You may also be interested in...
Risk-management plan is “impressive,” but needs supporting evidence, FDA advisors say.
New drugs help firm move on from fading Actiq, beset by generic erosion.
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.